Hepion Pharma up after fatty liver disease drug meets trial goals

Hepion Pharmaceuticals

22/05/2023 12:13

(Updates)
    ** Shares of Hepion Pharmaceuticals  HEPA.O  rise 45.3% to
$12.89 premarket 
    ** Says its experimental drug to treat a type of fatty liver
disease, non-alcoholic steatohepatitis (NASH), met the main and
secondary goals of a mid-stage study 
    ** The drug, rencofilstat, helped improve some measures of
liver impairment in the trial 
    ** HEPA shares have risen nearly 48% YTD 

 (Reporting by Manas Mishra)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15;))